Proteome Sciences plc (LON:PRM – Get Free Report) dropped 18.5% during trading on Thursday . The stock traded as low as GBX 2.89 ($0.04) and last traded at GBX 2.89 ($0.04). Approximately 1,014,536 shares were traded during trading, an increase of 367% from the average daily volume of 217,283 shares. The stock had previously closed at GBX 3.55 ($0.05).
Proteome Sciences Price Performance
The stock has a 50-day moving average of GBX 4.05 and a two-hundred day moving average of GBX 3.46. The company has a current ratio of 0.20, a quick ratio of 0.37 and a debt-to-equity ratio of -258.66. The firm has a market cap of £9.98 million, a price-to-earnings ratio of -2.45 and a beta of 0.07.
Proteome Sciences (LON:PRM – Get Free Report) last released its earnings results on Thursday, April 10th. The company reported GBX (1.15) (($0.02)) earnings per share (EPS) for the quarter. Proteome Sciences had a negative net margin of 0.04% and a negative return on equity of 0.01%.
About Proteome Sciences
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.
Featured Articles
- Five stocks we like better than Proteome Sciences
- How to buy stock: A step-by-step guide for beginners
- Robinhood Strategies Could Be a Game-Changer for Young Investors
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Are These 3 Retail Stocks Oversold or Really in Trouble?
- Energy and Oil Stocks Explained
- IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead
Receive News & Ratings for Proteome Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteome Sciences and related companies with MarketBeat.com's FREE daily email newsletter.